결핵 진료지침

9. Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009;48:1657-65.
10. Yildiz A, Sever MS, Türkmen A, Ecder T, Beşişik F, Tabak L, et al. Tuberculosis after renal transplantation: experience of one Turkish centre. Nephrol Dial Transplant 1998;13:1872-5.
11. Chiang CY, Chen CH, Feng JY, Chiang YJ, Huang WC, Lin YJ, et al. Prevention and management of tuberculosis in solid organ transplantation: A consensus statement of the transplantation society of Taiwan. J Formos Med Assoc 2023.
12. Talavera Pons S, Boyer A, Lamblin G, Chennell P, Châtenet FT, Nicolas C, et al. Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol 2017;83:269-93.
13. Agrawal A, Agarwal SK, Kaleekal T, Gupta YK. Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. Indian J Nephrol 2016;26:322-8.
14. Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Annals of Clinical Microbiology and Antimicrobials 2006;5:3.
15. Torre-Cisneros J, San-Juan R, Rosso-Fernández CM, Silva JT, Muñoz-Sanz A, Muñoz P, et al. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis 2015;60:1642-9.
16. Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after Solid-Organ Transplant: Incidence, Risk Factors, and Clinical Characteristics in the RESITRA (Spanish Network of Infection in Transplantation) Cohort. Clinical Infectious Diseases 2009;48:1657-65.
17. Roman A, Bravo C, Levy G, Monforte V, Vidal R, Solé J, et al. Isoniazid

VIII. 잠복결핵감염 <PAGE>365